Cardiomyopathy, Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
Conditions
Keywords
CSP 592, ICD, cardiovascular, heart, aging, chronic diseases, multi-site trial, investigational device, cardiomyopathy, coronary artery disease, congestive heart failure, myocardial infarction, I-70, I70, elderly, defibrillator
Brief summary
The overall aim of this trial is to study the safety and efficacy of ICD implantation as a primary prevention strategy of sudden cardiac death in patients 70 years and older. This study will assess the many competing factors involved with ICD implantation including 1) the impact on mortality, especially in the context of a declining rate of sudden death with advanced age, 2) the tolerability of the powerful therapeutic action of the device, and 3) the impact on quality of life.
Detailed description
The overall aim of this trial is to study the safety and efficacy of ICD implantation as a primary prevention strategy of sudden cardiac death (SCD) in patients 70 years and older. In particular, this study is designed to determine the comparative effectiveness of ICD, in addition to optimal medical therapy (OMT), in reducing all-cause mortality, versus OMT alone; OMT includes standard intervention for chronic heart failure patients, i.e. lifestyle modification, disease management, adoption of healthy diet and exercise practices, etcetera. One particularly important secondary objective is to assess treatment efficacy under the conditions of high versus low co-morbidity burden. Participants will be randomized (1:1 ratio) to ICD + OMT or OMT alone, and stratified by participating site and co-morbidity level (Charlson score \<3 versus 3+). Acute treatment visits will occur as clinically indicated and per local convention; follow-up will occur 1-4 months post-randomization (all participants), and not sooner than 30 days - and not later than 120 days post-implantation (ICD arm); regular follow-up will occur at 6 month intervals post-randomization until study close (all participants). All follow-up will be conducted centrally. Neither the participant nor treating clinician will be masked to treatment. Primary Objective: The primary objective of this study is to determine if a primary prevention strategy with ICD implantation in addition to optimal medical therapy (OMT) is effective in reducing all-cause mortality compared to OMT alone in patients 70 years of age and older who are eligible for ICD therapy according to current Centers for Medicare & Medicaid Services (CMS) criteria. Primary Hypothesis: The primary hypothesis of this study is that implantation of an ICD plus optimal medical therapy will reduce all-cause mortality in patients 70 years of age and older versus optimal medical therapy alone. Secondary Objectives: 1. One secondary objective of this study is to ascertain whether age, co-morbidity burden, or age and burden together, are determinants in mortality outcomes in the OMT versus ICD + OMT group. 2. An additional secondary objective of the study is to determine the effect of ICD implantation plus optimal medical therapy on quality of life among elderly patients compared with optimal medical therapy alone.
Interventions
The ICD and lead(s) will be FDA-approved.
Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
Sponsors
Study design
Eligibility
Inclusion criteria
1. 70 years of age or older 2. Eligible for ICD implementation according to the CMS criteria for primary prevention by one of the following conditions: 1. Documented prior MI and a measured left ventricular ejection fraction (LVEF) \<=30% (includes New York Heart Association \[NYHA\] class I, II, or III) 2. Coronary artery disease with a documented prior MI, a measured left ventricular ejection fraction \<=35%, and inducible, sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) at electrophysiology (EP) study 3. Ischemic dilated cardiomyopathy (IDCM), documented prior MI, NYHA class II and III heart failure, and measured LVEF \<=35% 4. Non-ischemic dilated cardiomyopathy (NIDCM) \> 3 months, NYHA Class II and III heart failure, and measured LVEF \<=35% 3. Stable condition on Optimal Medical Therapy 4. Able and willing to provide informed consent to participate in this study
Exclusion criteria
1. Enrolled in or planning to enroll in a conflicting trial 2. Receiving a bi-ventricular ICD device 3. New York Heart Association class IV heart failure 4. Cardiogenic shock or symptomatic hypotension while in stable baseline rhythm, 5. Coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months 6. An MI within the past 40 days 7. Clinical symptoms or findings that would make them a candidate for coronary revascularization 8. Irreversible brain damage from pre-existing cerebral disease 9. Any disease other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year 10. Circumstance that would prevent completion of the trial and follow-up activities, including medical condition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | Through study completion, starting from consent/baseline: average of 31 months. | All-cause mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life - Minnesota Living With Heart Failure Questionnaire | Measured at 12-months post-randomization | Minnesota Living with Heart Failure questionnaire. MLHF scoring: 0 points = Best QOL, 105 points = Worst QOL. |
| Sudden Cardiac Death | Through study completion, starting from consent/baseline: average of 31 months. | Sudden Cardiac Death |
| All-cause Hospitalization | Through study completion, starting from consent/baseline: average of 31 months. | Number of participants hospitalized during study follow-up |
Countries
United States
Participant flow
Recruitment details
Recruitment at six Department of Veterans Affairs Medical Centers (VAMCs). Recruitment start: 8/6/2015 (4) 9/25/2015 (1) and 10/29/2015 (1). Recruitment terminated: 12/6/2016 (1) and 12/5/2019 (5).
Pre-assignment details
None: Study design did not include significant events that occur after participant enrollment: no run-in phase, nor wash-out.
Participants by arm
| Arm | Count |
|---|---|
| Optimal Medical Therapy Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke. | 85 |
| Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD) Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke + FDA-Approved implantable cardioverter defibrillator and leads. | 82 |
| Total | 167 |
Baseline characteristics
| Characteristic | Optimal Medical Therapy | Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 85 Participants | 82 Participants | 167 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| New York Heart Association Class: I | 2 Participants | 4 Participants | 6 Participants |
| New York Heart Association Class: II | 62 Participants | 58 Participants | 120 Participants |
| New York Heart Association Class: III | 21 Participants | 20 Participants | 41 Participants |
| New York Heart Association Class: IV | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 12 Participants | 15 Participants | 27 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 73 Participants | 67 Participants | 140 Participants |
| Region of Enrollment United States | 85 Participants | 82 Participants | 167 Participants |
| Sex: Female, Male Female | 1 Participants | 1 Participants | 2 Participants |
| Sex: Female, Male Male | 84 Participants | 81 Participants | 165 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 23 / 85 | 20 / 82 |
| other Total, other adverse events | 1 / 85 | 6 / 82 |
| serious Total, serious adverse events | 67 / 85 | 62 / 82 |
Outcome results
Mortality
All-cause mortality
Time frame: Through study completion, starting from consent/baseline: average of 31 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Optimal Medical Therapy | Mortality | 23 Participants |
| Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD) | Mortality | 20 Participants |
All-cause Hospitalization
Number of participants hospitalized during study follow-up
Time frame: Through study completion, starting from consent/baseline: average of 31 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Optimal Medical Therapy | All-cause Hospitalization | 61 Participants |
| Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD) | All-cause Hospitalization | 60 Participants |
Quality of Life - Minnesota Living With Heart Failure Questionnaire
Minnesota Living with Heart Failure questionnaire. MLHF scoring: 0 points = Best QOL, 105 points = Worst QOL.
Time frame: Measured at 12-months post-randomization
Population: Analysis population differs from total number of study participants due to non-completion of the 12-month study visit, explained by either patient expiry or missed visit.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Optimal Medical Therapy | Quality of Life - Minnesota Living With Heart Failure Questionnaire | 11 score on a scale |
| Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD) | Quality of Life - Minnesota Living With Heart Failure Questionnaire | 13 score on a scale |
Sudden Cardiac Death
Sudden Cardiac Death
Time frame: Through study completion, starting from consent/baseline: average of 31 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Optimal Medical Therapy | Sudden Cardiac Death | 5 Participants |
| Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD) | Sudden Cardiac Death | 3 Participants |